Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 4, 2026, 8:55 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 386 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Oral antibiotics Clear all
Completed Phase 2 Interventional Accepts healthy volunteers

Efficacy of Immunization With 4C-MenB in Preventing Experimental Urethral Infection With Neisseria Gonorrhoeae

NCT05294588
View directory record Official record
Conditions
Gonorrhea Male
Interventions
Cefixime, Ceftriaxone, Ciprofloxacin, Neisseria gonorrhoeae strain FA1090, Meningococcal Group B Vaccine, Influenza Vaccine, Tetanus-diptheria Vaccine
Drug · Biological
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 35 Years · Male only
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Oct 4, 2026, 8:55 AM EDT
Completed Phase 4 Interventional

The Role of Antibiotics in Full Thickness Skin Graft Survival for Facial Reconstructive Surgery

NCT01912651
View directory record Official record
Conditions
Facial Defect
Interventions
cephalexin
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2025
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Oct 4, 2026, 8:55 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 TP-271 Oral PK Single Ascending Dose Study

NCT03024034
View directory record Official record
Conditions
Bacterial Infections
Interventions
TP-271
Drug
Lead sponsor
Tetraphase Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 50 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Dec 13, 2021 · Synced Oct 4, 2026, 8:55 AM EDT
Completed Phase 3 Interventional Results available

ERADICATE Hp - Treating Helicobacter Pylori With RHB-105

NCT01980095
View directory record Official record
Conditions
Dyspepsia, Helicobacter Pylori Infection
Interventions
RHB-105, Placebo
Drug
Lead sponsor
RedHill Biopharma Limited
Industry
Eligibility
18 Years to 65 Years
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
12
States / cities
Anaheim, California • Chino, California • Jupiter, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2019 · Synced Oct 4, 2026, 8:55 AM EDT
Completed Not applicable Interventional Results available

Recurrent Bacterial Vaginosis and Vaginal Acidifying Gel Trial

NCT00545181
View directory record Official record
Conditions
Bacterial Vaginosis
Interventions
Vaginal acidifying gel (RepHresh), Metronidazole control
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jan 12, 2010 · Synced Oct 4, 2026, 8:55 AM EDT
Completed Not applicable Interventional Results available

Intravenous Versus Intravenous/Oral Antibiotics for Perforated Appendicitis

NCT00462020
View directory record Official record
Conditions
Perforated Appendicitis
Interventions
5 days of IV antibiotics (ceftriaxone and metronidazole), Home with oral antibiotics when eating (ampicillin/clavulanic acid)
Drug
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
Up to 18 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 21, 2021 · Synced Oct 4, 2026, 8:55 AM EDT
Not listed Phase 3 Interventional Accepts healthy volunteers

Prospective Evaluation of Oral Antibiotics for Treatment of Shoulder PJI

NCT04636125
View directory record Official record
Conditions
Periprosthetic Infection, Oral Antibiotics, Revision Total Shoulder Arthroplasty
Interventions
Doxycycline 100 MG Oral Tablet
Drug
Lead sponsor
Rothman Institute Orthopaedics
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 19, 2020 · Synced Oct 4, 2026, 8:55 AM EDT
Recruiting Early Phase 1 Interventional

Self-Start Triage Model for Post-Botox® Lower Urinary Tract Symptoms

NCT07648290
View directory record Official record
Conditions
Overactive Bladder
Interventions
Macrobid® Capsules 100 mg, Standard Medical Care (SMC)
Drug · Other
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Oct 4, 2026, 8:55 AM EDT
Terminated Phase 2 Interventional Results available

Dose Finding Study of Nemiralisib (GSK2269557) in Subjects With an Acute Moderate or Severe Exacerbation of Chronic Obstructive Pulmonary Disease (COPD)

NCT03345407
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Placebo ELLIPTA, Nemiralisib ELLIPTA 50 µg, Nemiralisib ELLIPTA 100 µg, Nemiralisib ELLIPTA 250 µg, Nemiralisib ELLIPTA 500 µg, Nemiralisib ELLIPTA 750 µg, Albuterol (Salbutamol) MDI or nebules, Standard of care therapy
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years to 80 Years
Enrollment
943 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
21
States / cities
Mobile, Alabama • Colorado Springs, Colorado • Daytona Beach, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2021 · Synced Oct 4, 2026, 8:55 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of an Antibiotic Sponge in Diabetic Patients With a Mild Infection of a Foot Ulcer

NCT00593567
View directory record Official record
Conditions
Diabetic Foot Ulcer
Interventions
gentamicin-collagen sponge, Levofloxacin
Drug
Lead sponsor
Innocoll
Industry
Eligibility
18 Years to 80 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Pasadena, Maryland
Source: ClinicalTrials.gov public record
Updated May 31, 2022 · Synced Oct 4, 2026, 8:55 AM EDT
Completed Phase 2 Interventional Results available

ACX-362E [Ibezapolstat] for Oral Treatment of Clostridioides Difficile Infection

NCT04247542
View directory record Official record
Conditions
Clostridium Difficile Infection
Interventions
Ibezapolstat, Vancomycin
Drug
Lead sponsor
Acurx Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 90 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
29
States / cities
Scottsdale, Arizona • Apple Valley, California • Camarillo, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2025 · Synced Oct 4, 2026, 8:55 AM EDT
Recruiting Phase 2 Interventional

A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation

NCT06859424
View directory record Official record
Conditions
AML (Acute Myelogenous Leukemia), Acute Lymphoid Leukemia (ALL), Acute Leukemia (Category), MDS (Myelodysplastic Syndrome), CML (Chronic Myelogenous Leukemia), CLL (Chronic Lymphocytic Leukemia), Prolymphocyctic Leukemia, Chronic Myelomonocytic Leukemia (CMML), Myeloproliferative Neoplasm (MPN), Lymphoma, Myelofibrosis
Interventions
Conditioning Regimen A, Conditioning Regimen B, Conditioning Regimen C, Conditioning Regimen D, Conditioning Regimen E, Hematopoietic Cell Transplantation, PTCy (50 mg/kg D3, D4), PTCy (25 mg/kg D3, D4), Post-transplant Tacrolimus, Post-transplant Mycophenolate mofetil, Post-transplant Abatacept, Post-transplant Ruxolitinib, Supportive Care: Growth Factors, Supportive Care: Blood Products, Supportive Care: Infection Prophylaxis, Supportive Care: Intravenous immune globulin (IVIG), Supportive Care: Seizure prophylaxis, Supportive Care: Monitoring and management of CRS, Supportive Care: Prophylaxis against infections, Supportive Care: Prophylaxis against infections, Supportive Care: Lipid elevations, Study treatment compliance, Prohibited Concomitant Therapy, Permitted Concomitant Therapy
Drug · Procedure · Other
Lead sponsor
Center for International Blood and Marrow Transplant Research
Network
Eligibility
18 Years to 66 Years
Enrollment
358 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
13
States / cities
Birmingham, Alabama • Duarte, California • Palo Alto, California + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Oct 4, 2026, 8:55 AM EDT
Recruiting Phase 1 Interventional

Vancomycin Study in Multiple Sclerosis (MS)

NCT05539729
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Vancomycin, Placebo
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 50 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 4, 2026, 8:55 AM EDT
Completed Phase 2Phase 3 Interventional

Comparison of Two- Versus Three-antibiotic Therapy for Pulmonary Mycobacterium Avium Complex Disease

NCT03672630
View directory record Official record
Conditions
Mycobacterium Avium Complex, Nontuberculous Mycobacterium Infection
Interventions
Azithromycin, Ethambutol, Rifampin
Drug
Lead sponsor
Kevin Winthrop
Other
Eligibility
18 Years and older
Enrollment
474 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
25
States / cities
Loma Linda, California • San Diego, California • San Francisco, California + 21 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2026 · Synced Oct 4, 2026, 8:55 AM EDT
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

Infant Mortality Reduction by the Mass Administration of Azithromycin

NCT04716712
View directory record Official record
Conditions
Child Mortality
Interventions
Azithromycin, Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
1 Month to 11 Months
Enrollment
694,400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 13, 2025 · Synced Oct 4, 2026, 8:55 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Experimental Human Infection With Neisseria Gonorrhoeae

NCT03840811
View directory record Official record
Conditions
Gonococcal Infection
Interventions
Cefixime, Ceftriaxone, Ciprofloxacin, Neisseria gonorrhoeae strain FA1090 A26, Neisseria gonorrhoeae strain FA7537
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 36 Years · Male only
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 23, 2021 · Synced Oct 4, 2026, 8:55 AM EDT
Withdrawn Phase 2 Interventional

Probiotics for Girls With Recurring Urinary Tract Infections

NCT00789464
View directory record Official record
Conditions
Recurrent Urinary Tract Infection
Interventions
Lactobacillus reuteri DSM 17938, trimethoprim/sulfamethoxazole
Dietary Supplement · Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
3 Months to 17 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 18, 2020 · Synced Oct 4, 2026, 8:55 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Use of Prophylactic Antibiotics Prior to OnabotulinumtoxinA

NCT05519072
View directory record Official record
Conditions
Antibiotic Prophylaxis
Interventions
Nitrofurantoin
Drug
Lead sponsor
Atlantic Health System
Other
Eligibility
18 Years and older · Female only
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Morristown, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 27, 2024 · Synced Oct 4, 2026, 8:55 AM EDT
Terminated Early Phase 1 Interventional

Patients Response to Early Switch To Oral:Osteomyelitis Study

NCT02099240
View directory record Official record
Conditions
Osteomyelitis
Interventions
oral antibiotics, intravenous antibiotics
Drug · Procedure
Lead sponsor
Julio Ramirez
Other
Eligibility
18 Years to 100 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Apr 6, 2021 · Synced Oct 4, 2026, 8:55 AM EDT
Completed Phase 4 Interventional Results available

Randomized Trial of Culture Directed Versus Empiric Antibiotics for Urinary Tract Infections in Older Women

NCT05726318
View directory record Official record
Conditions
UTI
Interventions
Antibiotics
Drug
Lead sponsor
Megan Bradley
Other
Eligibility
65 Years and older · Female only
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 27, 2025 · Synced Oct 4, 2026, 8:55 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers

Oral Vancomycin for Secondary Prophylaxis of Clostridium Difficile Infection (CDI)

NCT04000555
View directory record Official record
Conditions
Clostridium Difficile Infection, Clostridium Difficile Infection Recurrence
Interventions
Oral Vancomycin, Placebo
Drug · Other
Lead sponsor
University of South Florida
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
2
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Apr 21, 2023 · Synced Oct 4, 2026, 8:55 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Safety and Efficacy of Fecal Microbiome Transplantation (FMT) in the Treatment of Antibiotic Dependent Pouchitis (ADP)

NCT02782325
View directory record Official record
Conditions
Pouchitis
Interventions
Active FMT, then open label FMT, Placebo FMT, then open label FMT
Biological
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 75 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 14, 2019 · Synced Oct 4, 2026, 8:55 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single and Multiple Ascending Dose Pharmacokinetic Study of TR701 in Healthy Adults

NCT00671814
View directory record Official record
Conditions
Healthy Subjects
Interventions
TR-701, linezolid, placebo
Drug
Lead sponsor
Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 50 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 31, 2017 · Synced Oct 4, 2026, 8:55 AM EDT
Completed Phase 2 Interventional Results available

Effectiveness of Antibiotic Delivery Via Bio-absorbable Sponge

NCT01222832
View directory record Official record
Conditions
Paranasal Sinus Disease
Interventions
Bacitracin
Drug
Lead sponsor
Steward St. Elizabeth's Medical Center of Boston, Inc.
Other
Eligibility
18 Years and older
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Brighton, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 31, 2017 · Synced Oct 4, 2026, 8:55 AM EDT